Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine immunologic responses in patients who have completed first-line therapy for Hodgkin's lymphoma treated with Hodgkin's antigens-GM-CSF-expressing cell vaccine.
* Determine the durability of these immunologic responses in these patients.
* Determine the utility of an Epstein-Barr virus reporter system for monitoring cellular vaccine responses.
* Determine the safety and tolerability of this vaccine in these patients.
OUTLINE: Beginning 4-6 months after last chemotherapy, patients receive Hodgkin's antigens-GM-CSF-expressing cell vaccine on day 1. Treatment repeats every 3 weeks for up to 4 courses.
Immunologic responses are serially monitored along with disease status.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of classic Hodgkin's lymphoma
Must have completed first-line therapy without evidence of disease progression
PATIENT CHARACTERISTICS:
HIV negative
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No more than 6 months since prior chemotherapy or radiotherapy
Clareo Health | Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
